All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2018-10-30T13:51:04.000Z

ESH MM 2018 | Continuous or fixed-duration therapy in multiple myeloma?

Oct 30, 2018
Share:

Bookmark this article

The 4th International Conference on Multiple Myeloma, organized by the European School of Haematology (ESH), took place on 5–7 of October 2018 in Mandelieu, France. The conference not only offered the opportunity to learn about current clinical practice and established guidelines but also to hear different views on hot topics in multiple myeloma (MM).

A debate that took place during the conference addressed the arguments for and against continuous versus fixed-duration therapy in newly diagnosed (ND) MM.

Thierry Facon from the University Hospital of Lille, France, supported the idea that continuous therapy should be the standard of care, based on results from several clinical trials: the Myeloma XI study has shown that maintenance therapy with lenalidomide is associated with a significantly longer median progression-free survival (PFS) compared to observation only; the HOVON-65/GMMG-HD4 trial showed that bortezomib maintenance favours patients with del17p; the ALCYONE trial has revealed superior PFS in patients treated with daratumumab in combination with bortezomib/melphalan/prednisone (VMP) compared to those treated with VMP alone, due to the maintenance treatment with daratumumab; the FIRST trial showed that NDMM patients ineligible for ASCT, who achieved complete or very good partial response and received continuous treatment with lenalidomide/dexamethasone (Rd), had a significantly longer PFS compared to those treated with Rd for a fixed duration of 18 cycles (Rd18).

Jesús San Miguel from the University Clinic of Navarra in Pamplona, Spain, did not support continuous nor fixed-duration treatment, but individualized-duration therapy, highlighting that continuous is not the same as prolonged treatment. There are several drawbacks to continuous treatment. These include: toxicity; high cost; and the trial design that usually compares maintenance with no treatment at all, rather than with a fixed-duration treatment. Moreover, results from clinical trials do not show a difference in overall survival (OS) after one or a maximum of two years maintenance therapy. Continuous therapy does not take into account prior response to treatment or the unique biological characteristics of each patient, such as the cytogenetic or monoclonal gammopathy of undetermined significance (MGUS) profile or the immune signature. It can be argued that after two years of heavy treatment, maintenance therapy is unlikely to benefit patients who have achieved partial response but may benefit those who have achieved complete response rates. The ideal scenario would be to adapt treatment options to match individual needs. If a patient has achieved a less than very good partial response (≤VGPR), she/he should be offered the option to change treatment rather than continue with the maintenance therapy.

The main conclusion of the debate was that both continuous and fixed-duration therapies should be considered and the best option will be a personalized one dependent on each patient’s disease features and personal needs.

References:

  1. Thierry Facon. Continuous therapy. 4th International Conference in Multiple Myeloma, European School of Haematology (ESH), Mandelieu, France.
  2. Jesús San Miguel. Fixed duration. 4th International Conference in Multiple Myeloma, European School of Haematology (ESH), Mandelieu, France.

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 39 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox